ViiV Healthcare presents GEMINI 1 & 2 studies through Week 96 showing 2-drug regimen of dolutegravir plus lamivudine continues to demonstrate high efficacy rates and no cases of treatment emergent resistance - Argus Press

ViiV Healthcare presents GEMINI 1 & 2 studies through Week 96 showing 2-drug regimen of dolutegravir plus lamivudine continues to demonstrate high efficacy rates and no cases of treatment emergent resistance  Argus Press

LONDON--(BUSINESS WIRE)--Jul 24, 2019--. ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited ...



Comments

Popular posts from this blog

The Best Flea Treatments for Cats and Dogs

Is Citronella Safe for Dogs? A Veterinarian Provides Guidance

Everything You Need to Know About Mite and Flea Bites